Aplastic Anemia and Bone Marrow Failure

• Hematopoietic stem cell deficiency and dysfunction: Severe reduction in CD34+ hematopoietic stem cell numbers and impaired replicative capacity. In acquired aplastic anemia, immune-mediated destruction of stem cells occurs via CD8+ T cell-mediated cytotoxicity targeting hematopoietic cells, supported by aberrant production of IFN-γ and TNF-α. Molecular mechanisms include death receptor pathways (FAS/FASL interaction) and cytotoxic granule release. Telomerase deficiency is characteristic of inherited aplastic anemia syndromes (Fanconi anemia, dyskeratosis congenita), leading to accelerated replicative senescence and stem cell exhaustion.

• Bone marrow microenvironment damage and stromal dysfunction: Quantitative and qualitative abnormalities in marrow stroma, including fibroblasts, endothelial cells, and adipocytes that comprise the hematopoietic niche. Damage results in impaired production of critical growth factors (thrombopoietin [TPO], stem cell factor [SCF], angiopoietin-1) and abnormal cytokine milieu. In drug-induced and radiation-induced cases, direct toxic injury to both stem cells and stromal elements initiates the cascade. The marrow transforms from hyperplastic to hypoplastic with replacement by fat spaces, reducing the capacity for hematopoietic recovery.

• Impaired hematopoietic growth factor signaling: Reduced responsiveness to physiologic hematopoietic growth factors including erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), and thrombopoietin (TPO). Stem cells demonstrate intrinsic defects in signal transduction and reduced clonogenic potential in colony-forming assays. This explains the limited efficacy of single growth factor therapy and the need for combined immunosuppressive or stem cell transplantation approaches.

• Idiopathic (~50-70% of acquired cases): No identifiable cause despite thorough evaluation; likely represents unrecognized immune-mediated damage or environmental exposure.
• Drug-induced (~20-25% of cases): Chemotherapy agents (alkylating agents, methotrexate, nucleoside analogs), antibiotics (chloramphenicol [now rare, but classic teaching], sulfonamides, trimethoprim-sulfamethoxazole), anticonvulsants (phenytoin), NSAIDs, allopurinol, penicillamine. Risk may be dose-dependent (chemotherapy) or idiosyncratic (chloramphenicol).
• Radiation-induced: Accidental exposure, therapeutic radiation, nuclear accidents. Dose-dependent relationship; marrow aplasia typically occurs 4-6 weeks post-exposure.
• Infectious agents: Hepatitis-associated aplastic anemia (seronegative non-A, non-B, non-C hepatitis accounts for ~5-10% of cases in some series); rarely associated with Epstein-Barr virus, cytomegalovirus, parvovirus B19, and HIV.
• Immune-mediated conditions: Systemic lupus erythematosus, Sjögren syndrome, rheumatoid arthritis with secondary aplastic anemia.
• Pregnancy-associated: Rare, typically occurring in third trimester; may relate to altered immune tolerance.

Inherited/Constitutional Aplastic Anemia

• Fanconi anemia: Autosomal recessive (primarily) DNA repair disorder with characteristic chromosome fragility and progressive bone marrow failure; accounts for ~5% of aplastic anemia in children. High cancer predisposition (acute myeloid leukemia, squamous cell carcinomas).
• Dyskeratosis congenita: X-linked (most common) or autosomal recessive telomerase deficiency; classic triad of reticulate pigmentation, nail dystrophy, and oral leukoplakia. Progressive marrow failure in first and second decades.
• Severe congenital neutropenia (Kostmann syndrome): Mutations in ELANE, GFI1, or other genes; presents with selective neutropenia progressing to aplasia.
• Shwachman-Diamond syndrome: SBDS gene mutations; pancreatic insufficiency with progressive marrow failure.

• Anemia-related symptoms: Dyspnea on exertion, fatigue, syncope, palpitations, and pallor. Severe normocytic anemia (hemoglobin often <7 g/dL at presentation) develops insidiously over weeks to months in acquired forms; symptoms may be masked initially if onset is gradual. Physical findings include conjunctival pallor, palmar pallor, and hyperkinetic precordium.

• Thrombocytopenia-related bleeding: Petechiae and purpura (particularly non-blanching, lower extremities and pressure-dependent areas) reflecting platelet counts typically <50,000/μL. Mucosal bleeding (epistaxis, hemoptysis, hematochezia, hematuria, severe menorrhagia), retinal hemorrhages, and life-threatening intracranial hemorrhage in severe cases. Bleeding may be spontaneous or provoked; severity correlates with platelet nadirs.

• Neutropenia-related infections: Recurrent, severe, atypical infections due to absolute neutrophil count (ANC) typically <500/μL. Bacterial (gram-positive skin flora, gram-negative enterics), fungal (Candida, Aspergillus), and opportunistic infections (Pneumocystis jirovecii pneumonia if severe/prolonged). Fever may be absent due to inability to mount inflammatory response. Oral ulcerations, pharyngitis, perirectal infections are characteristic.

• Constitutional symptoms: Low-grade fever (from cytokine production or infection), malaise, arthralgias (particularly in immune-mediated forms).

• Hepatomegaly/splenomegaly: Modest splenomegaly in ~25% of cases (from extramedullary hematopoiesis or infiltration); massive splenomegaly should prompt consideration of alternative diagnoses.

• Findings specific to inherited forms: Fanconi anemia patients may have short stature, skeletal abnormalities (thumb/radial anomalies), microcephaly, café-au-lait spots. Dyskeratosis congenita: reticulate hyperpigmentation of chest/neck, nail dystrophy, oral leukoplakia/erythroplaquia.

Complete blood count (CBC) and differential

• Pancytopenia with normocytic, normochromic anemia (hemoglobin <10 g/dL typically); reticulocyte count inappropriately low (reticulocyte index <1.0), reflecting impaired marrow response.
• Platelets <50,000/μL; often <20,000/μL in severe disease.
• Absolute neutrophil count <1,500/μL; severe aplasia defined by ANC <500/μL.
• Peripheral blood smear: Shows reduced erythrocytes, leukocytes, and platelets with no dysplastic features (distinguishing aplastic anemia from myelodysplastic syndrome). Absence of blasts, dyserythropoiesis, or abnormal morphology.

• Gross pathology: Marrow is hypocellular, fatty, and gray-tan rather than normal red/pink cellular marrow. May appear gelatinous or fibrotic in severe cases.
• Histopathology: Severe hypocellularity (<25% cellularity) with replacement by fatty infiltration and fibrin/edema. Normal architecture preserved but acellular spaces predominate. Residual hematopoietic cells are morphologically normal without dysplastic changes (no abnormal mitoses, dysmorphic precursors, or increased blasts). Megakaryocytes markedly reduced or absent. T-lymphocyte infiltrates may be present, supporting immune-mediated etiology. Iron stains show preserved iron in macrophages (ruling out iron deficiency).

• Bone marrow cellularity <25% AND
• Two of three peripheral findings:
• Neutrophils <500/μL
• Platelets <20,000/μL
• Reticulocytes <60,000/μL

Laboratory evaluation

• Reticulocyte index: Low, reflecting impaired erythropoiesis despite anemia.
• Iron studies: Normal to elevated serum iron and ferritin (from transfusions and hemolysis); transferrin saturation elevated.
• Vitamin B12 and folate levels: Normal (ruling out megaloblastic anemia).
• Hemolysis markers (LDH, bilirubin, haptoglobin): Usually normal or mildly abnormal.
• Cytogenetics of bone marrow: Typically normal karyotype in acquired aplastic anemia; abnormalities (monosomy 7, complex karyotype) suggest myelodysplastic syndrome or clonal evolution.
• Flow cytometry: CD34+ cell count <0.5% suggests poorer prognosis; useful for detecting paroxysmal nocturnal hemoglobinuria (PNH) co-occurrence (~10-25% of aplastic anemia cases).

Specialized testing

• Chromosome breakage analysis (DEB/MMC test): For suspected Fanconi anemia; demonstrates increased chromosome fragility.
• Telomere length analysis: Shortened in dyskeratosis congenita and some acquired cases.
• Clonogenic assays (CFU-GM, BFU-E): Reduced or absent colonies; research use.
• Immunophenotyping for PNH: Flow cytometry with CD55/CD59 analysis on blood cells.

Imaging

• Chest X-ray: To evaluate for infections, evaluate cardiac silhouette for transfusion-related cardiomyopathy.
• Abdominal ultrasound: To assess for splenomegaly, hepatomegaly, or other pathology.
• HLA typing: For all patients being considered for allogeneic stem cell transplantation.

• Red blood cell transfusions: Target hemoglobin 7-8 g/dL to minimize iron overload; use leukoreduced and irradiated blood products to prevent alloimmunization and transfusion-related graft-versus-host disease (GVHD) in transplant candidates.
• Platelet transfusions: Maintain >20,000/μL; higher thresholds (>50,000/μL) for active bleeding or CNS complications. Avoid HPA-alloimmunization via single-donor apheresis products or HPA-matched transfusions.
• Infection prophylaxis and management: HEPA filtration, prophylactic antibiotics (fluoroquinolone), antifungal prophylaxis (fluconazole or itraconazole for ANC <500 prolonged), and aggressive empiric broad-spectrum antibiotics for fever. Prophylactic PCP prophylaxis (trimethoprim-sulfamethoxazole) if CD4 equivalent low.
• Iron chelation: Initiation after 10-20 units of transfused RBCs using deferoxamine, deferiprone, or deferasirox to prevent secondary hemochromatosis and organ damage.

Disease-modifying therapy

• Immunosuppressive therapy (IST) (first-line for older patients or those without suitable donor):
• Antithymocyte globulin (ATG): Equine ATG (ATGAM) or rabbit ATG (Thymoglobulin); doses 40 mg/kg/day IV for 4 days. Mechanism: depletes T-lymphocytes implicated in stem cell destruction. Response rates 50-70% in acquired aplastic anemia.
• Cyclosporine A (CSA): 5-10 mg/kg/day divided dosing, targeting trough levels 200-400 ng/mL. Inhibits IL-2 production and T cell activation. Used in combination with ATG for synergistic effect. Response rates improved to 60-75% with combination therapy.
• Corticosteroids: Low-dose prednisone (0.5-1 mg/kg/day) concurrent with ATG/CSA; tapered over several weeks to months. Reduces serum sickness and augments immunosuppressive effect.
• Response assessment at 3 months; non-responders may benefit from second course or alternative therapy. Median response time 2-3 months.

• Hematopoietic stem cell transplantation (HSCT) (preferred curative therapy, especially for younger patients with suitable donor):
• Allogeneic HSCT from HLA-matched sibling donor: Gold standard; 5-year survival rates 75-90% in patients <20 years, declining with age. Conditioning regimen typically cyclophosphamide-based (CY 120-200 mg/kg) ± ATG. Risk of GVHD (acute and chronic) and relapse (~10%).
• Matched unrelated donor HSCT: Higher GVHD risk but acceptable outcomes; 5-year survival 60-75% depending on age and donor matching quality. HLA compatibility (10/10 match vs. mismatches) significantly impacts outcome.
• Haploidentical HSCT: Increasingly used; post-transplantation cyclophosphamide (PTCy) to prevent GVHD; outcomes approaching matched unrelated donor transplants.
• Timing: Recommended for severe aplastic anemia in patients <50 years with suitable donor; considered in very severe disease regardless of age given high mortality without transplant.

• Growth factor therapy: Limited efficacy as monotherapy; G-CSF and/or TPO-receptor agonists (eltrombopag, romiplostim) may be used adjunctively:
• Eltrombopag: TPO-mimetic; improves platelet counts and may promote stem cell expansion; increasingly used with IST or as bridge to transplant. Shows synergy with IST.
• G-CSF: Helps with absolute neutrophil recovery but does not improve long-term outcome as monotherapy; used to support patients during treatment.

Treatment selection algorithm

• Age <50 years with HLA-matched sibling donor: Allogeneic HSCT (first-line).
• Age <50 years without sibling donor but suitable matched unrelated donor: HSCT after search (after initial IST trial or concurrent with IST if very severe).
• Age ≥50 years OR patient/family declines transplant: IST (ATG + CSA ± corticosteroids); if no response, consider second course or HSCT if patient remains suitable.
• Very severe aplastic anemia (ANC <200/μL): Urgent treatment; may proceed directly to HSCT if suitable donor available given high mortality.

• Infectious complications (most common in acute phase): Bacterial sepsis, invasive fungal infections (particularly Aspergillus in prolonged severe neutropenia), viral reactivation (CMV, herpes simplex). Fatal outcome in 10-20% of cases during initial management phase.

• **Hemorrhag

• The classic picture: pancytopenia + low absolute reticulocyte count + a hypocellular, fat-replaced marrow on core biopsy (the aspirate is often scant or dilute) with no blasts, no dysplasia, and no fibrosis. Intact architecture with empty spaces = production failure, not peripheral destruction. A true dry tap should instead raise suspicion for myelofibrosis or hairy cell leukemia, not aplastic anemia.
• Single best next step when a stem shows unexplained pancytopenia with reticulocytopenia: bone marrow aspirate and biopsy. The core biopsy (not the aspirate) establishes cellularity and is required before any disease-modifying therapy.
• Drug and toxin associations examiners love: chloramphenicol (idiosyncratic, dose-independent aplasia of uncertain mechanism — distinct from its separate dose-dependent, reversible marrow suppression), benzene, ionizing radiation, phenytoin/carbamazepine, sulfonamides, and gold/penicillamine. Note that propylthiouracil and methimazole are classically tested for agranulocytosis (isolated neutropenia), not true aplastic anemia. Withdrawal of the offending agent is always part of the answer.
• The association most often tested: overlap with paroxysmal nocturnal hemoglobinuria — order flow cytometry for loss of GPI-anchored proteins (CD55/CD59). Long-term, survivors are at risk of clonal evolution to MDS/AML; a new monosomy 7 or complex karyotype changes the diagnosis.
• Common distractor #1 — parvovirus B19: causes pure red cell aplasia (isolated anemia, giant pronormoblasts), not pancytopenia; in sickle cell disease this is an aplastic crisis.
• Common distractor #2 — pancytopenia with a hypercellular marrow: think B12/folate deficiency (hypersegmented neutrophils, ineffective erythropoiesis), MDS, or hypersplenism. Splenomegaly argues strongly against aplastic anemia. A leukoerythroblastic smear with teardrop cells points to myelophthisis or myelofibrosis.
• Pediatric stem clues: short stature, absent/hypoplastic thumbs, café-au-lait macules → Fanconi anemia; confirm with chromosomal breakage testing (DEB/mitomycin C). Nail dystrophy, oral leukoplakia, reticulated pigmentation → dyskeratosis congenita.
• Transfusion and infection pitfalls: use leukoreduced, irradiated cellular products and avoid family-member directed donations in potential transplant candidates (alloimmunization risk), consistent with AABB guidance; for febrile neutropenia, give empiric broad-spectrum antipseudomonal beta-lactam therapy (e.g., cefepime or piperacillin-tazobactam) per the IDSA 2010 guideline on antimicrobial use in neutropenic patients with cancer, with outpatient management reserved for low-risk patients per the 2018 ASCO/IDSA update.